TWI888599B - 取代哌啶化合物及其用途 - Google Patents

取代哌啶化合物及其用途 Download PDF

Info

Publication number
TWI888599B
TWI888599B TW110126031A TW110126031A TWI888599B TW I888599 B TWI888599 B TW I888599B TW 110126031 A TW110126031 A TW 110126031A TW 110126031 A TW110126031 A TW 110126031A TW I888599 B TWI888599 B TW I888599B
Authority
TW
Taiwan
Prior art keywords
compound
mmol
azabicyclo
added
solution
Prior art date
Application number
TW110126031A
Other languages
English (en)
Chinese (zh)
Other versions
TW202216705A (zh
Inventor
吉田融
北陽一
小竹真
反町啓一
大房俊行
元木貴史
浅羽太郎
Original Assignee
日商衛材R&D企管股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商衛材R&D企管股份有限公司 filed Critical 日商衛材R&D企管股份有限公司
Publication of TW202216705A publication Critical patent/TW202216705A/zh
Application granted granted Critical
Publication of TWI888599B publication Critical patent/TWI888599B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pain & Pain Management (AREA)
TW110126031A 2020-07-17 2021-07-15 取代哌啶化合物及其用途 TWI888599B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-122864 2020-07-17
JP2020122864 2020-07-17

Publications (2)

Publication Number Publication Date
TW202216705A TW202216705A (zh) 2022-05-01
TWI888599B true TWI888599B (zh) 2025-07-01

Family

ID=79291962

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110126031A TWI888599B (zh) 2020-07-17 2021-07-15 取代哌啶化合物及其用途

Country Status (19)

Country Link
US (1) US11479552B2 (enExample)
EP (1) EP4151277A4 (enExample)
JP (1) JP7190612B2 (enExample)
KR (1) KR20230040953A (enExample)
CN (3) CN115884971B (enExample)
AR (1) AR122973A1 (enExample)
AU (1) AU2021308053A1 (enExample)
BR (1) BR112022026161A2 (enExample)
CA (1) CA3187835A1 (enExample)
CL (1) CL2022003666A1 (enExample)
CO (1) CO2022018446A2 (enExample)
IL (1) IL299125B1 (enExample)
MX (1) MX2022016388A (enExample)
PE (1) PE20231103A1 (enExample)
PH (1) PH12022553488A1 (enExample)
TW (1) TWI888599B (enExample)
UA (1) UA129636C2 (enExample)
WO (1) WO2022014680A1 (enExample)
ZA (1) ZA202213562B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4065585T1 (sl) 2019-11-25 2025-11-28 Alkermes, Inc. Substituirane makrociklične spojine ter z njimi povezani postopki zdravljenja
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US20250051322A1 (en) * 2022-01-14 2025-02-13 Eisai R&D Management Co., Ltd. Crystal of substituted piperidine compound, salts of substituted piperidine compound, and crystals thereof
JP7591592B2 (ja) * 2022-01-14 2024-11-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 置換ピペリジン化合物を含有する医薬
IL319940A (en) * 2022-10-07 2025-05-01 Kissei Pharmaceutical Cyclopentane compound
CN120129521A (zh) * 2022-10-31 2025-06-10 武田药品工业株式会社 食欲素2型受体激动剂的给药
JPWO2024128305A1 (enExample) 2022-12-16 2024-06-20
TW202502342A (zh) 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素2受體促效劑用於改善睡眠期間之呼吸功能的用途
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025137359A1 (en) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517032A (ja) * 2004-10-20 2008-05-22 ノイロサーチ アクティーゼルスカブ 新規なジアザ二環式アリール誘導体及びその医薬用途
JP4765627B2 (ja) * 2003-09-22 2011-09-07 Msd株式会社 新規ピペリジン誘導体
JP2016512536A (ja) * 2013-03-13 2016-04-28 ヤンセン ファーマシューティカ エヌ.ベー. 置換した7−アザビシクル及びオレキシン受容体調節因子としてのそれらの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG34208A1 (en) 1995-03-01 1996-12-06 Guy Andrew Vaz Blast and fragment resistant polyurethane boot sole for safety footwear
WO1996034877A1 (en) 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Human neuropeptide receptor
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6159605A (en) 1997-02-18 2000-12-12 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Ink-jet recording sheet
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
KR100327888B1 (ko) 1999-07-14 2002-03-09 정숭렬 도로포장 파손촉진 시험장치의 무선제어 시스템
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4765627B2 (ja) * 2003-09-22 2011-09-07 Msd株式会社 新規ピペリジン誘導体
JP2008517032A (ja) * 2004-10-20 2008-05-22 ノイロサーチ アクティーゼルスカブ 新規なジアザ二環式アリール誘導体及びその医薬用途
JP2016512536A (ja) * 2013-03-13 2016-04-28 ヤンセン ファーマシューティカ エヌ.ベー. 置換した7−アザビシクル及びオレキシン受容体調節因子としてのそれらの使用

Also Published As

Publication number Publication date
PE20231103A1 (es) 2023-07-19
US20220017517A1 (en) 2022-01-20
CA3187835A1 (en) 2022-01-20
MX2022016388A (es) 2023-01-30
JP7190612B2 (ja) 2022-12-15
JPWO2022014680A1 (enExample) 2022-01-20
CL2022003666A1 (es) 2023-05-26
AR122973A1 (es) 2022-10-19
CN119258067A (zh) 2025-01-07
UA129636C2 (uk) 2025-06-18
CN115884971B (zh) 2024-11-05
AU2021308053A1 (en) 2023-02-02
ZA202213562B (en) 2023-10-25
IL299125A (en) 2023-02-01
CN119235864A (zh) 2025-01-03
PH12022553488A1 (en) 2024-04-22
KR20230040953A (ko) 2023-03-23
TW202216705A (zh) 2022-05-01
CN115884971A (zh) 2023-03-31
WO2022014680A1 (ja) 2022-01-20
EP4151277A1 (en) 2023-03-22
CO2022018446A2 (es) 2023-03-07
EP4151277A4 (en) 2024-06-26
IL299125B1 (en) 2025-11-01
US11479552B2 (en) 2022-10-25
BR112022026161A2 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
TWI888599B (zh) 取代哌啶化合物及其用途
TW201018663A (en) Fluorene compound and pharmaceutical use thereof
JP6533799B2 (ja) 放射標識された化合物
JP2024517498A (ja) 化合物
KR101800140B1 (ko) 벤조티아졸론 화합물
TW202432509A (zh) 對於食慾素-2受體拮抗劑之製備有用之方法及化合物、以及雜質少之萊博雷生
US20250011280A1 (en) Deuterated organic compounds and uses thereof
EP4438602A1 (en) Crystal of substituted piperidine compound, salts of substituted piperidine compound, and crystals thereof
JP7591592B2 (ja) 置換ピペリジン化合物を含有する医薬
RU2840772C1 (ru) Замещенные пиперидиновые соединения и их применение
US20250091990A1 (en) Deuterated organic compounds and uses thereof
TW202542144A (zh) 取代哌啶化合物及其用途
EA045865B1 (ru) Замещенные пиперидиновые соединения и их применение
HK40083601B (zh) 取代的哌啶化合物及其用途
HK40083601A (en) Substituted piperidine compound and application thereof
JP6851318B2 (ja) ピラゾール誘導体の結晶
CN118804746A (zh) 氘代有机化合物及其用途